Hybio Pharmaceutical Balance Sheet Health
Financial Health criteria checks 1/6
Hybio Pharmaceutical has a total shareholder equity of CN¥774.2M and total debt of CN¥1.7B, which brings its debt-to-equity ratio to 220.2%. Its total assets and total liabilities are CN¥3.0B and CN¥2.2B respectively.
Key information
220.2%
Debt to equity ratio
CN¥1.71b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥45.30m |
| Equity | CN¥774.25m |
| Total liabilities | CN¥2.22b |
| Total assets | CN¥2.99b |
Recent financial health updates
Here's Why Hybio Pharmaceutical (SZSE:300199) Can Afford Some Debt
Jul 20
Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?
Feb 26Recent updates
Here's Why Hybio Pharmaceutical (SZSE:300199) Can Afford Some Debt
Jul 20Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) Price Is Out Of Tune With Revenues
Jun 03Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) 27% Share Price Surge Not Quite Adding Up
Feb 29Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?
Feb 26Financial Position Analysis
Short Term Liabilities: 300199's short term assets (CN¥421.1M) do not cover its short term liabilities (CN¥1.0B).
Long Term Liabilities: 300199's short term assets (CN¥421.1M) do not cover its long term liabilities (CN¥1.2B).
Debt to Equity History and Analysis
Debt Level: 300199's net debt to equity ratio (214.4%) is considered high.
Reducing Debt: 300199's debt to equity ratio has increased from 57.7% to 220.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 300199 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 300199 has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.5% each year.